Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric oncology group/children's cancer group phase II study 9457 - A report from the children's oncology group
Topotecan had limited activity in patients with Ewing sarcoma or PNET metastatic at diagnosis. The topotecan-cyclophosphamide combination was active. Amifostine was not myeloprotective. Overall results showed no improvement compared with previous studies.